Patent intelligence · US
US 6028106
Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or …
Patent details — US 6028106
- Jurisdiction
- US
- Status
- expired
- Grant date
- Feb 22, 2000
- Expiration
- Feb 17, 2020
- Applicant
- Board of Regents, The Univ. of TX System
- Claims
- 9
- CPC classes
- A61K, A61K31/198, A61K31/21, A61K31/295
Quick answer
US 6028106 (Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents) is held by Board of Regents, The Univ. of TX System. Status: expired. Granted Feb 22, 2000. Expires Feb 17, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Board of Regents, The Univ. of TX System
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/198, A61K31/21, A61K31/295, A61K31/34, A61K31/56
More from Board of Regents, The Univ. of TX System
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 6028106?
US 6028106 (Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents) is held by Board of Regents, The Univ. of TX System. Status: expired. Granted Feb 22, 2000. Expires Feb 17, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6028106?
Board of Regents, The Univ. of TX System is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 6028106 expire?
Our index shows an expiration date of Feb 17, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.